Apiol is the parsley-associated phenylpropene more commonly standardized in modern databases as apiole. In AromaForge context it is best treated as an identity and safety-significant constituent of parsley materials rather than a wellness-active ingredient: current evidence supports its occurrence in parsley oils, CYP1A interaction in preclinical systems, and a broader alkenylbenzene toxicology discussion that warrants conservative pregnancy and dose framing. Human clinical evidence for isolated apiol is sparse, and historical abortifacient use should be treated as safety context rather than benefit language.
Chemical identity and composition
PubChem groups Apiol and Apiole under the same CID 10659 and CAS 523-80-8, with the preferred title returned as Apiole. This record preserves the archive's `apiol` identifier because parsley-seed oil already uses that spelling, while noting that modern chemical databases usually normalize the isolated compound to apiole.
Aroma and practical use
- Use the recorded green, herbal, spicy, woody, herbaceous descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
cyp1a interaction research
A 2024 PubMed abstract reported that apiole inhibited CYP1A1 and CYP1A2-associated activity, reduced MeIQx-linked revertant colonies in TA98, and was not mutagenic on its own in that assay.
Measured: CYP1A-associated activity and MeIQx-linked mutagenicity
This experimental finding does not establish benefit, dose or safety in people using this blend.
alkenylbenzene safety context
A Food and Chemical Toxicology abstract snippet reported that rat-liver formation of the 1'-sulfoxy metabolite was predicted to be about three times lower for apiol than for safrole, enabling a preliminary read-across risk assessment rather than a direct human safety clearance.
Measured: predicted bioactivation and margin-of-exposure framing
This experimental finding does not establish benefit, dose or safety in people using this blend.
acaricidal research
A PubMed-indexed paper title and snippet identify apiol from parsley seeds as an active constituent in acaricidal testing, which is relevant as agricultural bioactivity evidence rather than human-use evidence.
Measured: mite toxicity
This experimental finding does not establish benefit, dose or safety in people using this blend.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
A recorded constituent reference, not a recommended oil dilution. Product category, source applicability and all contributing oils must be checked before use.
unverified reference · No source provenance attachedHistorical literature and current secondary references associate parsley apiol with abortifacient use and hepato-renal toxicity at high doses, so pregnancy-related framing should stay conservative.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
The strongest modern toxicology signal located in this pass is not a human trial but alkenylbenzene risk-modeling and metabolism work that uses safrole read-across because direct tumor data for apiol are limited.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Because apiole/apiol may inhibit CYP1A enzymes in preclinical systems, herb-drug interaction language is more defensible than any claim of therapeutic benefit.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
mixed type cyp1a inhibition
Apiole was reported to inhibit CYP1A-associated activities and to behave as a mixed-type inhibitor of recombinant human CYP1A1 in a 2024 mechanistic paper.
This experimental finding does not establish benefit, dose or safety in people using this blend.
lower predicted 1 prime sulfoxy metabolite formation than safrole
PBK modeling predicted lower formation of the 1'-sulfoxy metabolite for apiol than for safrole, which is a toxicology mechanism signal rather than a statement of safety at arbitrary doses.
This experimental finding does not establish benefit, dose or safety in people using this blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (5)
- No human clinical trials of isolated apiol were located in the reviewed public sources.
- The archive currently uses both `apiol` and `apiole` as constituent IDs even though major databases normalize them to the same compound, so future cleanup may want an explicit canonical/preferred-id policy.
- A constituent-specific dermal exposure limit or fragrance-monograph style safety review for isolated apiol was not verified in this pass.
- The numeric dermal reference lacks source provenance; a verified flag alone is insufficient.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.